Arjun Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arjun Patel has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Vipul Chimanlal Chitalia
Renal Section, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA
3 shared publications - Anna Natrakul
Department of Medicine, Renal Section, Boston University Chobanian & Avedisian School of Medicine, Boston, MA
2 shared publications - Asha Jose
Department of Medicine, Renal Section, Boston University Chobanian & Avedisian School of Medicine, Boston, MA
2 shared publications - Isaac Sellinger
Renal Section, Department of Medicine, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts
2 shared publications - Katya Ravid
Department of Medicine and Whitaker Cardiovascular Institute, Boston University Chobanian & Avedisian School of Medicine, Boston, MA
2 shared publications - Saran Lotfollahzadeh
Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts
2 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 3 (4) , 100209
Endothelial indoleamine 2,3-dioxygenase 1 drives high-tryptophan diet–mediated thrombosis in cancer-bearing mice
- 28 August 2026
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 3 (4) , 100209
Open AccessEndothelial indoleamine 2,3-dioxygenase 1 drives high-tryptophan diet–mediated thrombosis in cancer-bearing mice
- 21 August 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Indoxyl Sulfate Promotes Uremic Arterial and Venous Thrombosis by Stabilizing Indoleamine 2,3-Dioxygenase 1 via the E3 Ligase Split-Hand/Foot Malformation 3
Key Points: Indoleamine 2,3-dioxygenase 1 is a central regulator of tryptophan metabolism and contributed to CKD-associated thromboinflammation and endothelial dysfunction. Indoxyl sulfate, a protein-bound uremic toxin, stabilized indoleamine 2,3-dioxygenase 1 by partially inhibiting its interaction with split-hand/foot malformation 3 and reducing ubiquitination. Targeting indoleamine 2,3-dioxygenase 1 degradation by modulating split-hand/foot malformation 3 may offer a novel therapeutic approach to mitigate CKD-associated arterial and venous thrombosis. Background: The uremic milieu of CKD is characterized by the accumulation of protein-bound uremic toxins, which contribute to thrombosis. Indoxyl sulfate, a bona fide uremic toxin, upregulates indoleamine 2,3-dioxygenase 1 (IDO1), thereby augmenting kynurenine biogenesis. Both toxins activate tissue factor and thrombosis. Despite this pathogenic synergy, the mechanisms of indoxyl sulfate–mediated IDO1 stabilization remain undefined. Methods: We employed targeted metabolomics, super-resolution microscopy, and gain- and loss-of-function experiments using nanoparticle-mediated gene delivery in mice to modulate split-hand/foot malformation 3 (SHFM3) expression. This was followed by carotid artery or inferior vena cava thrombosis assays in indoxyl sulfate–fed and adenine-induced CKD models. Results: Among several F-box–containing E3 ligases, SHFM3 downregulated IDO1 in endothelial cells. SHFM3 constitutively interacted with IDO1, which is partially disrupted by indoxyl sulfate–induced nuclear sequestration of SHFM3 at concentrations corresponding to early-to-advanced CKD. SHFM3 interacted with the N-terminus of IDO1, ubiquitinated, and destabilized it. Indoxyl sulfate upregulated IDO1 activity, thereby increasing kynurenine biogenesis in N-terminus– and SHFM3-dependent manners. In an indoxyl sulfate–fed mouse model, endothelial cell–specific SHFM3 knockdown increased IDO1 and tissue factor while accelerating arterial thrombosis, and these effects were reversed by endothelial cell–specific SHFM3 overexpression. CKD mice exhibited 55% higher venous thrombogenicity than controls. Endothelial cell–specific SHFM3 overexpression significantly reversed these effects in control mice and, to a lesser extent, in CKD mice. Serum indoxyl sulfate levels significantly correlated with the global IDO1 activity and venous clot weights. Conclusions: SHFM3 functions as an indoxyl sulfate–sensitive potent E3 ligase of IDO1, targeting it for degradation, even with partial interaction with IDO1 in the uremic milieu. This work also described a CKD-induced venous thrombosis model and supports the selective rewiring of uremic toxins in post-translational proteostasis, amplifying indoxyl sulfate–mediated arterial and venous thrombosis.
- 21 August 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Indoxyl Sulfate Promotes Uremic Arterial and Venous Thrombosis by Stabilizing Indoleamine 2,3-Dioxygenase 1 via the E3 Ligase Split-Hand/Foot Malformation 3
Key Points: Indoleamine 2,3-dioxygenase 1 is a central regulator of tryptophan metabolism and contributed to CKD-associated thromboinflammation and endothelial dysfunction. Indoxyl sulfate, a protein-bound uremic toxin, stabilized indoleamine 2,3-dioxygenase 1 by partially inhibiting its interaction with split-hand/foot malformation 3 and reducing ubiquitination. Targeting indoleamine 2,3-dioxygenase 1 degradation by modulating split-hand/foot malformation 3 may offer a novel therapeutic approach to mitigate CKD-associated arterial and venous thrombosis. Background: The uremic milieu of CKD is characterized by the accumulation of protein-bound uremic toxins, which contribute to thrombosis. Indoxyl sulfate, a bona fide uremic toxin, upregulates indoleamine 2,3-dioxygenase 1 (IDO1), thereby augmenting kynurenine biogenesis. Both toxins activate tissue factor and thrombosis. Despite this pathogenic synergy, the mechanisms of indoxyl sulfate–mediated IDO1 stabilization remain undefined. Methods: We employed targeted metabolomics, super-resolution microscopy, and gain- and loss-of-function experiments using nanoparticle-mediated gene delivery in mice to modulate split-hand/foot malformation 3 (SHFM3) expression. This was followed by carotid artery or inferior vena cava thrombosis assays in indoxyl sulfate–fed and adenine-induced CKD models. Results: Among several F-box–containing E3 ligases, SHFM3 downregulated IDO1 in endothelial cells. SHFM3 constitutively interacted with IDO1, which is partially disrupted by indoxyl sulfate–induced nuclear sequestration of SHFM3 at concentrations corresponding to early-to-advanced CKD. SHFM3 interacted with the N-terminus of IDO1, ubiquitinated, and destabilized it. Indoxyl sulfate upregulated IDO1 activity, thereby increasing kynurenine biogenesis in N-terminus– and SHFM3-dependent manners. In an indoxyl sulfate–fed mouse model, endothelial cell–specific SHFM3 knockdown increased IDO1 and tissue factor while accelerating arterial thrombosis, and these effects were reversed by endothelial cell–specific SHFM3 overexpression. CKD mice exhibited 55% higher venous thrombogenicity than controls. Endothelial cell–specific SHFM3 overexpression significantly reversed these effects in control mice and, to a lesser extent, in CKD mice. Serum indoxyl sulfate levels significantly correlated with the global IDO1 activity and venous clot weights. Conclusions: SHFM3 functions as an indoxyl sulfate–sensitive potent E3 ligase of IDO1, targeting it for degradation, even with partial interaction with IDO1 in the uremic milieu. This work also described a CKD-induced venous thrombosis model and supports the selective rewiring of uremic toxins in post-translational proteostasis, amplifying indoxyl sulfate–mediated arterial and venous thrombosis.
- Open Access
- 5 September 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (9) , 1238-1250
Aryl Hydrocarbon Receptor Pathway Augments Peritoneal Fibrosis in a Murine CKD Model Exposed to Peritoneal Dialysate
Key Points: CKD and high glucose–containing peritoneal dialysate alter peritoneal membrane contributing to peritoneal dialysis failure, with a poorly understood mechanism. CKD milieu activates the aryl hydrocarbon receptor pathway in the subperitoneal vasculature, increasing the peritoneal fibrosis and collagen deposition in humans and mice. An aryl hydrocarbon receptor inhibitor mitigates CKD and peritoneal dialysis–mediated peritoneal fibrosis, collagen deposition, and vasculogenesis in a mouse model. Background: CKD is a proinflammatory and profibrotic condition and can independently alter the peritoneal membrane structure. Peritoneal dialysis (PD) results in profound alterations in the peritoneal membrane. The mechanisms contributing to the alterations of the peritoneal membrane structure in CKD milieu, along with PD, are poorly understood. Methods: Here, we show that human CKD induces peritoneal membrane thickening, fibrosis, and collagen deposition and activates the aryl hydrocarbon receptor (AHR) pathway in the subperitoneal vasculature. Leveraging a novel model of PD in CKD mice, we confirm these CKD-induced changes in the peritoneal membrane, which are exacerbated on exposure to the peritoneal dialysate. Peritoneal dialysate further augmented the AHR activity in endothelial cells of peritoneal microvasculature in CKD mice. Results: Treatment of CKD mice with an AHR inhibitor in peritoneal dialysate for 2 weeks resulted in a seven-fold reduction in AHR expression in the endothelial cells of subperitoneal capillaries, a five-fold decrease in subperitoneal space, and a nine-fold decrease in fibrosis and collagen deposition compared with vehicle-treated CKD mice. AHR inhibition reduced inflammation, subperitoneal neovascular areas, and its downstream target, tissue factor. The AHR inhibitor treatment normalized the peritoneal dialysate-induced proinflammatory and profibrotic cytokines, such as IL-6, monocyte chemoattractant protein-1, and macrophage inflammatory protein 1 levels, in CKD mice. Conclusions: This study uncovers the activation of the AHR-cytokine axis in the endothelial cells of subperitoneal vessels in humans and mice with CKD, which is likely to prime the peritoneal membrane to peritoneal dialysate–mediated alterations. This study supports further exploration of AHR as a potential therapeutic target to preserve the structural and functional integrity of the peritoneal membrane in PD.
- 5 September 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (9) , 1238-1250
Open AccessAryl Hydrocarbon Receptor Pathway Augments Peritoneal Fibrosis in a Murine CKD Model Exposed to Peritoneal Dialysate
Key Points: CKD and high glucose–containing peritoneal dialysate alter peritoneal membrane contributing to peritoneal dialysis failure, with a poorly understood mechanism. CKD milieu activates the aryl hydrocarbon receptor pathway in the subperitoneal vasculature, increasing the peritoneal fibrosis and collagen deposition in humans and mice. An aryl hydrocarbon receptor inhibitor mitigates CKD and peritoneal dialysis–mediated peritoneal fibrosis, collagen deposition, and vasculogenesis in a mouse model. Background: CKD is a proinflammatory and profibrotic condition and can independently alter the peritoneal membrane structure. Peritoneal dialysis (PD) results in profound alterations in the peritoneal membrane. The mechanisms contributing to the alterations of the peritoneal membrane structure in CKD milieu, along with PD, are poorly understood. Methods: Here, we show that human CKD induces peritoneal membrane thickening, fibrosis, and collagen deposition and activates the aryl hydrocarbon receptor (AHR) pathway in the subperitoneal vasculature. Leveraging a novel model of PD in CKD mice, we confirm these CKD-induced changes in the peritoneal membrane, which are exacerbated on exposure to the peritoneal dialysate. Peritoneal dialysate further augmented the AHR activity in endothelial cells of peritoneal microvasculature in CKD mice. Results: Treatment of CKD mice with an AHR inhibitor in peritoneal dialysate for 2 weeks resulted in a seven-fold reduction in AHR expression in the endothelial cells of subperitoneal capillaries, a five-fold decrease in subperitoneal space, and a nine-fold decrease in fibrosis and collagen deposition compared with vehicle-treated CKD mice. AHR inhibition reduced inflammation, subperitoneal neovascular areas, and its downstream target, tissue factor. The AHR inhibitor treatment normalized the peritoneal dialysate-induced proinflammatory and profibrotic cytokines, such as IL-6, monocyte chemoattractant protein-1, and macrophage inflammatory protein 1 levels, in CKD mice. Conclusions: This study uncovers the activation of the AHR-cytokine axis in the endothelial cells of subperitoneal vessels in humans and mice with CKD, which is likely to prime the peritoneal membrane to peritoneal dialysate–mediated alterations. This study supports further exploration of AHR as a potential therapeutic target to preserve the structural and functional integrity of the peritoneal membrane in PD.